https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-strengthens-executive-leadership-to-accelerate-clinical-development-efforts/2026-04-27T12:48:08-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-strengthens-scientific-advisory-board-with-expert-appointments-to-advance-pipeline-programs/2026-04-27T12:47:49-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-announces-positive-topline-data-from-phase-2a-study-evaluating-cmtx-101-in-cystic-fibrosis/2026-04-27T12:47:17-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-strengthens-leadership-team-to-accelerate-pipeline-and-corporate-development-progress/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-announces-completion-of-enrollment-in-phase-2a-study-of-cmtx-101-in-cystic-fibrosis/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-announces-fda-grant-of-fast-track-and-qualified-infectious-disease-product-designations-for-cmtx-101/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-announces-positive-interim-analysis-in-phase-2a-study-evaluating-cmtx-101-for-infections-associated-with-cystic-fibrosis/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/cincytech-invests-in-clarametyx-to-advance-breakthrough-anti-biofilm-therapies-for-chronic-respiratory-disease/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-announces-investment-by-kineticos-amr-accelerator-fund/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-awarded-a-multi-phased-agreement-with-carb-x-to-accelerate-anti-biofilm-vaccine-to-prevent-bacterial-infections/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-bioscience-recognized-as-infectious-disease-innovation-of-the-year-in-2024-biotech-breakthrough-awards/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-announces-progress-on-study-of-antibody-therapy-cmtx-101-for-infections-associated-with-cystic-fibrosis/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-to-present-on-its-anti-biofilm-technology-platform-during-antimicrobial-pipeline-session-at-idweek-2024/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-appoints-renowned-experts-to-augment-strategic-and-scientific-advisory-boards/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-expands-team-expertise-to-accelerate-pipeline-momentum/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-announces-33-million-series-a-financing-to-advance-anti-biofilm-biologics-for-serious-bacterial-infections/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-announces-positive-early-phase-1-safety-findings-on-cmtx-101-immune-enabling-antibody-therapy/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-announces-changes-to-its-scientific-advisory-board/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-initiates-phase-1-study-of-immune-enabling-antibody-therapy-cmtx-101-against-community-acquired-bacterial-pneumonia/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/clarametyx-announces-fda-acceptance-of-investigational-new-drug-ind-application-for-phase-1-study-of-immune-enabling-antibody-therapy-cmtx-101/2026-05-01T14:39:57-04:00https://clarametyx.koii.dev/articles/article/carb-x-awards-clarametyx-biosciences-3-89-million-in-additional-option-funding-to-accelerate-anti-biofilm-technology-for-life-threatening-bacterial-infections/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-awarded-3-15-million-grant-from-nih-to-advance-a-broad-spectrum-vaccine-technology-for-bacterial-infections/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/new-publication-in-cell-implicates-a-rare-form-of-dna-driving-antimicrobial-resistance-in-bacterial-biofilms/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-awarded-2-7-million-in-option-funding-from-carb-x-to-accelerate-novel-technology-for-persistent-bacterial-infections/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-expands-board-of-directors-with-appointment-of-financial-executive-michael-layman/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/clarametyx-featured-in-2021-technology-showcase-hosted-by-nationwide-childrens-hospitals-office-of-technology-commercialization/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/david-richards-appointed-ceo-of-clarametyx-biosciences/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/newly-published-insights-in-biofilm-illustrate-the-powerful-mechanisms-of-an-antibody-biofilm-eradication-therapy-approach/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-awarded-up-to-14-2-million-from-carb-x-to-accelerate-novel-immune-enabling-technology-to-combat-persistent-bacterial-infections/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/data-published-in-ebiomedicine-validates-novel-scientific-approach-that-disarms-bacterial-defenses-to-treat-or-prevent-life-threatening-infections/2026-05-01T14:40:07-04:00https://clarametyx.koii.dev/articles/article/clarametyx-biosciences-launches-with-an-ambitious-strategy-to-address-life-threatening-bacterial-infections/2026-05-01T14:40:07-04:00